Q1 FY27 saw 29% revenue growth and 126% net profit increase, driven by strong CDMO and Affordable Medicines performance. Gross and EBITDA margins expanded, with significant CAPEX and R&D investments supporting future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.